公开(公告)号：US10772928B2

公开(公告)日：2020-09-15

申请号：US15536416

申请日：2015-12-15

Applicant: The Governing Council of the University of Toronto ,  Sinai Health System

Inventor： Benjamin J. Blencowe ,  Mathieu Quesnel-Vallieres ,  Manuel Irimia ,  Bushra Raj ,  Sabine P. Cordes

IPC: A61K38/55 ,  A61K38/05 ,  A61K31/7088 ,  G01N33/68 ,  C12Q1/6883 ,  A61K38/46 ,  G01N33/50 ,  A01K67/027 ,  C07K14/47 ,  A61K45/06 ,  A61K31/713 ,  A61K49/00

Abstract: Methods for treatment and diagnosis of neurological disorders such as autism and autism spectrum disorder are disclosed. Also disclosed are modulators of alternative splicing regulators SRRM4 and/or SRRM3 for treating neurological disorders. Further disclosed are agents that modulate the expression of at least one splice variant for treating neurological disorders. Mouse models of neurological disorders having increased or decreased expression of SRRM4 and/or SRRM3 are also disclosed.

公开(公告)号：US20180073039A1

公开(公告)日：2018-03-15

申请号：US15554042

申请日：2016-03-01

Applicant: Sinai Health System

Inventor： Daniel Durocher ,  Alexandre Orthwein ,  Sylvie Noordermeer

IPC: C12N15/90 ,  A61K31/713 ,  C12N15/10 ,  C12N15/113 ,  C07K14/47 ,  C12N15/67 ,  C12Q1/68

CPC classification number: C12N15/902 ,  A61K31/713 ,  C07K14/47 ,  C12N9/00 ,  C12N15/00 ,  C12N15/09 ,  C12N15/102 ,  C12N15/113 ,  C12N15/1138 ,  C12N15/63 ,  C12N15/67 ,  C12N15/90 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/20 ,  C12N2310/531 ,  C12N2800/80 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/178

Abstract: The invention relates to factors that influence or regulate homologous recombination, methods to monitor these factors, the use of these factors to screen for agents that modulate homologous recombination, and methods to activate or modulate homologous recombination.

公开(公告)号：US20180044686A1

公开(公告)日：2018-02-15

申请号：US15556146

申请日：2016-03-09

Applicant: Sinai Health System

Inventor： Andras NAGY ,  Claudio MONETTI ,  Qin LIANG

IPC: C12N15/65 ,  C12N15/90 ,  C12N15/85

CPC classification number: C12N15/65 ,  C12N5/0606 ,  C12N5/10 ,  C12N15/85 ,  C12N15/907

Abstract: The present disclosure provides molecular tools, methods and kits for using cell division loci (CDLs) to control cell proliferation in animal cells. CDLs, as provided herein, are loci whose transcription product(s) are expressed during cell division. CDLs may be genetically modified, as described herein, to comprise a negative selectable marker and/or an inducible activator-based gene expression system, which allows a user to permit, ablate, and/or inhibit proliferation of the genetically modified cell(s) by adding or removing an appropriate inducer.

公开(公告)号：US09408934B2

公开(公告)日：2016-08-09

申请号：US14055365

申请日：2013-10-16

Applicant: Sinai Health System

Inventor： Thomas Willett

IPC: A61L2/00 ,  A61L9/00

CPC classification number: A61L9/00 ,  A61L2/00 ,  A61L27/3608 ,  A61L27/365 ,  A61L27/3683 ,  A61L27/3687 ,  A61L2430/02 ,  A61L2430/40

Abstract: The present invention relates to compositions, methods, kits and systems employing irradiation activated agents to improve or increase or prevent loss of toughness, work-to-fracture, post-yield toughness, fracture toughness and/or fatigue strength of a bone allograft on exposure to radiation. The irradiation activated agent can be an agent that increases crosslinking of collagen in bone during irradiation, for example ribose, 2-hydroxytetrahydropyran or ascorbate.

Abstract translation: 本发明涉及组合物，方法，试剂盒和使用照射活化剂以改善或增加或增加暴露于骨骼同种异体移植物的韧性，工作对断裂，后屈服韧性，断裂韧性和/或疲劳强度的组合物，方法，试剂盒和系统 到辐射。 照射活化剂可以是在照射期间增加骨中胶原蛋白交联的试剂，例如核糖，2-羟基四氢吡喃或抗坏血酸。

公开(公告)号：US12178835B2

公开(公告)日：2024-12-31

申请号：US18175409

申请日：2023-02-27

Applicant: Sinai Health System

Inventor： Andras Nagy ,  Jeffrey Harding ,  Kristina Nagy

IPC: C12N5/0735 ,  A61K35/545 ,  A61K45/06 ,  A61P1/16 ,  A61P3/00 ,  A61P3/10 ,  A61P7/04 ,  A61P9/10 ,  A61P19/02 ,  A61P25/16 ,  A61P27/02 ,  A61P37/06 ,  C07K14/47 ,  C07K14/52 ,  C07K14/705 ,  C12N15/09

Abstract: A cell genetically modified to comprise at least one mechanism for providing a local immunosuppression at a transplant site when transplanted in an allogeneic host is, and methods for making and using the same is provided. The cell comprises a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting, and whose function is one or more of: to mitigate antigen presenting cell activation and function; to mitigate graft attacking leukocyte activity or cytolytic function; to mitigate macrophage cytolytic function and phagocytosis of allograft cells; to induce apoptosis in graft attacking leukocytes; to mitigate local inflammatory proteins; and to protect against leukocyte-mediated apoptosis.

公开(公告)号：US11078475B2

公开(公告)日：2021-08-03

申请号：US16098620

申请日：2017-05-03

Applicant: UNIVERSITY HEALTH NETWORK ,  Sinai Health System

Inventor： Daniel Diniz De Carvalho ,  Shu Yi Shen ,  Rajat Singhania

IPC: C12Q1/68 ,  C12N15/10 ,  C12Q1/6806 ,  C12Q1/6804 ,  G01N33/53 ,  C12Q1/6886 ,  C40B30/04

Abstract: There is described herein, a method of capturing cell-free methylated DNA from a sample having less than 100 mg of cell-free DNA, comprising the steps of: subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated; denaturing the sample; and capturing cell-free methylated DNA using a binder selective for methylated polynucleotides.

公开(公告)号：US20200308651A1

公开(公告)日：2020-10-01

申请号：US16630299

申请日：2018-07-11

Applicant: UNIVERSITY HEALTH NETWORK ,  SINAI HEALTH SYSTEM

Inventor： Daniel Diniz DE CARVALHO ,  Scott Victor BRATMAN ,  Rajat SINGHANIA ,  Ankur Ravinarayana CHAKRAVARTHY ,  Shu Yi SHEN

IPC: C12Q1/6886 ,  C12Q1/6827

Abstract: There is described herein a method of detecting the presence of DNA from cancer cells in a subject comprising: providing a sample of cell-free DNA from a subject; subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated, then optionally denaturing the sample; capturing cell-free methylated DNA using a binder selective for methylated polynucleotides; sequencing the captured cell-free methylated DNA; comparing the sequences of the captured cell-free methylated DNA to control cell-free methylated DNAs sequences from healthy and cancerous individuals and from individuals with distinct cancer types and subtypes; identifying the presence of DNA from cancer cells if there is a statistically significant similarity between one or more sequences of the captured cell-free methylated DNA and cell-free methylated DNAs sequences from cancerous individuals.

公开(公告)号：US20190010196A1

公开(公告)日：2019-01-10

申请号：US16073501

申请日：2017-01-31

Applicant: The Governing Council of the University of Toronto ,  Sinai Health System

Inventor： Daniel Durocher ,  Sachdev Sidhu ,  Wei Zhang ,  Frank Sicheri ,  Marella Canny

IPC: C07K14/47 ,  C12N15/62 ,  C12N15/113 ,  C12N9/22

Abstract: 53BP1 inhibitors, compositions comprising the inhibitors and methods of using same are provided. The inhibitors can be used in combination with gene editing systems.

公开(公告)号：US10006921B2

公开(公告)日：2018-06-26

申请号：US15360240

申请日：2016-11-23

Applicant: Sinai Health System

Inventor： Keith Jarvi ,  Eleftherios P. Diamandis ,  Andrei Drabovich

IPC: G01N33/53 ,  G01N33/68

CPC classification number: G01N33/6893 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/68 ,  G01N33/689 ,  G01N2333/705 ,  G01N2333/78 ,  G01N2800/34 ,  G01N2800/342 ,  G01N2800/367

Abstract: Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides, encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for urogenital conditions employing urogenital markers, polynucleotides encoding the markers, and/or binding agents for the markers.

公开(公告)号：US20250144154A1

公开(公告)日：2025-05-08

申请号：US18949799

申请日：2024-11-15

Applicant: Sinai Health System

Inventor： Andras Nagy ,  Jeffrey Harding ,  Kristina Nagy

IPC: A61K35/545 ,  A61K45/06 ,  A61P1/16 ,  A61P3/00 ,  A61P3/10 ,  A61P7/04 ,  A61P9/10 ,  A61P19/02 ,  A61P25/16 ,  A61P27/02 ,  A61P37/06 ,  C07K14/47 ,  C07K14/52 ,  C07K14/705 ,  C12N5/0735 ,  C12N15/09

Abstract: A cell genetically modified to comprise at least one mechanism for providing a local immunosuppression at a transplant site when transplanted in an allogeneic host is, and methods for making and using the same is provided. The cell comprises a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting, and whose function is one or more of: to mitigate antigen presenting cell activation and function; to mitigate graft attacking leukocyte activity or cytolytic function; to mitigate macrophage cytolytic function and phagocytosis of allograft cells; to induce apoptosis in graft attacking leukocytes; to mitigate local inflammatory proteins; and to protect against leukocyte-mediated apoptosis.